Abstract
Lay Summary Biosimilar medications have the potential to significantly reduce the cost of treatment in patients with inflammatory bowel disease. Observational studies have shown similar efficacy and safety of biosimilars to biologic reference products. Shared decision-making is crucial to the successful implementation of these agents.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have